Insmed to Discuss Litigation Settlement with Tercica
07 Mars 2007 - 5:24AM
Business Wire
Insmed (NASDAQ:INSM) announced that it will host a conference call
on Wednesday, March 7 at 11:00 a.m. (ET) to discuss the litigation
settlement with Genentech and Tercica, and other business details.
Among participants on the call will be Geoffrey Allan, Ph.D.,
president and CEO of Insmed and Kevin Tully, Executive Vice
President and CFO. Interested investors can listen to the call over
the Internet from Insmed's investor relations website at
www.insmed.com or by dialing (888) 802-2225 (domestic) or (913)
312-1268 (international). A telephonic replay of the call will be
available for two weeks, by dialling (888) 203-1112 (domestic) or
(719) 457-0820 (international). The passcode # is 4396908. A web
replay of the call will be available through the corporate website.
About Insmed Insmed Inc. is a biopharmaceutical company focused on
the development and commercialization of drug candidates for the
treatment of metabolic diseases and endocrine disorders with unmet
medical needs. For more information, please visit www.insmed.com
Insmed Safe Harbor Statement Statements included within this press
release, which are not historical in nature, may constitute
forward-looking statements for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release include, but are
not limited to, statements regarding business strategies, growth
opportunities for approved or proposed products, plans and
objectives of management. Such forward-looking statements are
subject to numerous risks and uncertainties, including risks that
our product candidates may fail in clinical trials or may not be
successfully marketed, we may lack financial resources to complete
development of product candidates, we may be unable to raise
additional financing necessary to continue current operations
competing products may be more successful, demand for new
pharmaceutical products may decrease and the biopharmaceutical
industry may experience negative market trends. As a result of
these and other risks and uncertainties, actual results may differ
materially from those described in this press release. For further
information with respect to factors that could cause actual results
to differ from expectations, reference is made to reports filed by
the Company with the Securities and Exchange Commission under the
Securities Exchange Act of 1934, as amended. The forward-looking
statements made in this release are made only as of the date hereof
and Insmed disclaims any intention or responsibility for updating
predictions or financial guidance contained in this release.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024